Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib in Advanced ROS1+ Non-Small Cell Lung Cancer

    NEXT STORY
    Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (axicabtagene ciloleucel) With lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    PREV STORY
    Aptose to Present at the Jefferies 2019 Healthcare Conference
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Immunomedics Reports Results For Period Ended December 31, 2018, Strengthens Board And Announces Senior Leadership Changes

    author_avatar
    NASDAQ Market News

    MPI’s spinout Oncology Venture’s second drug candidate in the clinic – First Multiple Myeloma patient in study with APO010, an Immuno-Oncology drug

    Hoersholm, Denmark, May 31st, 2017 - Medical Prognosis Institute A/S (MPI:ST) today announced that ...

    author_avatar
    NASDAQ Market News

    Flexion Therapeutics Reports Third Quarter 2016 Financial Results

    Successfully completed the transfer of the Zilretta™ manufacturing technology to Patheon - on track ...

    author_avatar
    NASDAQ Market News